Innovate Biopharmaceuticals

2026/03/03

About Us

Innovate Biopharmaceuticals is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, operating at the intersection of gastroenterology and autoimmune disease research. North Carolina’s Research Triangle has been our base for a deliberate reason: the region concentrates one of the densest clusters of academic medical centers, contract research organizations, and biopharmaceutical talent pipelines in the United States, and that infrastructure directly supports the kind of clinical development work that defines our operational model.

We are not a company built around a broad portfolio of early-stage bets. Our focus is narrow by design, concentrated on gastrointestinal conditions where the existing standard of care leaves a measurable and documented gap between what patients need and what currently approved therapies can deliver.

Our founding premise was that the GI disease space, particularly celiac disease and inflammatory bowel conditions, had been underinvested relative to the size of the affected population and the severity of the unmet need. Approximately 3 million Americans have been diagnosed with celiac disease, and a significant subset of that population continues to experience persistent symptoms despite strict adherence to a gluten-free diet. That specific patient group, referred to clinically as non-responsive celiac disease, had no approved pharmacological treatment option when Innovate began its development program, and that absence of alternatives is what shaped our pipeline from the ground up.

Pipeline and Clinical Milestones

Our lead development program centered on larazotide acetate, a first-in-class tight junction regulator that works by reinforcing the intestinal barrier at the epithelial level, reducing gut permeability that drives ongoing inflammation and symptom persistence in celiac patients who are already on a gluten-free diet.

The compound is not an immunosuppressant and does not interfere with the underlying immune response to gluten in the way that most investigational celiac therapies do. It operates at the structural level of the intestinal wall, which gives it a differentiated mechanism and a tolerability profile that distinguished it from competing approaches throughout clinical evaluation.

Phase 2b data for larazotide acetate, published in Gastroenterology, demonstrated statistically significant symptom reduction at the 0.5mg three-times-daily dosing regimen compared to placebo across a multi-site trial population. That result was specific enough in its responder profile to support advancement into Phase 3 and to generate meaningful interest from gastroenterology researchers who had been watching the tight junction modulation space for years without a viable clinical candidate to work with.

The Phase 3 program represented one of the only celiac-specific investigational treatments to reach that stage in the history of the disease category.

Beyond larazotide, Innovate has maintained active research interests in microbiome-targeting therapeutics for inflammatory bowel disease and in compounds addressing gastrointestinal motility disorders, areas where patient volume is large and where current pharmaceutical options are either poorly tolerated or effective only in a narrow subset of the diagnosed population.

Products Distribution and Partnership

In 2026, Innovate Biopharmaceuticals formalized a distribution and patient access agreement with Arecov Mexican Pharmacy, a licensed pharmacy from CDMX operating across Mexico with an established cross-border patient base along the U.S.-Mexico corridor.

The objective of this partnership is to extend access to select Innovate-associated gastrointestinal support compounds and licensed OTC products into a market where specialist GI care is geographically concentrated in major urban centers and largely inaccessible to patients in smaller cities and border communities.

From Innovate’s perspective, this partnership serves two functions that a standard distribution agreement would not.

  1. First, it places our products in the hands of a patient population that shares many of the same disease characteristics as U.S. trial participants but has had no meaningful access to the pharmacological approaches developed for those conditions.
  2. Second, it generates longitudinal utilization data from a demographically distinct population, which adds clinical depth to our existing datasets and strengthens the body of real-world evidence that regulatory agencies increasingly weigh alongside controlled trial results.

Arecov’s existing patient communication infrastructure and its licensed pharmacy network made it the most operationally aligned partner for this type of cross-border access program without requiring Innovate to pursue a standalone Mexico regulatory filing on an accelerated timeline.
Leadership and Contact

Innovate Biopharmaceuticals is led by Blake Warner, who serves as President and Chief Executive Officer. Warner has guided the company’s clinical strategy through its most significant development milestones and continues to lead its pipeline advancement and partnership development efforts.

Products Under the Distribution Agreement

The product scope under the Innovate-Arecov agreement covers three categories that align directly with Innovate’s GI-focused development history and Arecov’s existing dispensing capabilities.

Contact

Key Press Releases and Public Milestones

For readers who want to go deeper into Innovate’s clinical history directly from primary sources, the following press releases and publications cover the most significant events in the company’s development timeline: